Michael Palazzo, PhD
Psychiatric/Mental Health, Adult · Honolulu, HINPI 1699902957
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $40,483 of the $62,704 with a category attached, or 64.6%. Teva Pharmaceuticals USA, Inc. accounts for 77.5% of it on its own, with 14 other manufacturers making up the rest. 2025 is the largest year on record at $23,307, 8.0 times the $2,913 reported in 2021.
Across 603 payments — averaging $103.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$49K
- Alkermes, Inc.$3K
- Neurocrine Biosciences, Inc.$2K
- Indivior Inc.$2K
- Johnson & Johnson$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- plus $4K from 9 others
What the payments were for
- Speaking & faculty fees$40,48365%
- Travel & lodging$3,3635%
- Food & beverage$18,63030%
- Education$2280%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 194 | $48,579 |
| Alkermes, Inc. | 79 | $3,007 |
| Neurocrine Biosciences, Inc. | 47 | $2,022 |
| Indivior Inc. | 54 | $1,850 |
| Johnson & Johnson | 52 | $1,592 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 43 | $1,492 |
| AbbVie | 55 | $1,365 |
| Otsuka America Pharmaceutical, Inc. | 43 | $1,270 |
| E.r. Squibb & Sons, L.L.C. | 19 | $626 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $353 |
| Janssen Scientific Affairs, LLC | 3 | $299 |
| Lundbeck LLC | 7 | $138 |
| Vanda Pharmaceuticals Inc. | 2 | $44 |
| Intuitive Surgical | 1 | $42 |
| Avanir Pharmaceuticals, Inc. | 1 | $25 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$27,039
- Austedo XR$18,366
- LYBALVI$4,205
- ARISTADA$1,771
- INGREZZA$1,269
- CAPLYTA$928
- INVEGA SUSTENNA$515
- ABILIFY MAINTENA$478
- AUSTEDO$471
- SUBLOCADE$377
- VRAYLAR$360
- ARISTADA INITIO$340
- COBENFY$281
- ABILIFY ASIMTUFII$252
- SPRAVATO$250
- REXULTI$245
- PERSERIS$244
- INVEGA TRINZA$125
- AJOVY$118
How this compares
Too few psychiatric/mental health, adult providers in Hawaiito place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 42 | $441,245 |
| Abilify MaintenaAripiprazole | 114 | $327,649 |
| AristadaAripiprazole Lauroxil | 101 | $315,659 |
| Invega SustennaPaliperidone Palmitate | 73 | $263,721 |
| Austedo XrDeutetrabenazine | 11 | $164,267 |
| PerserisRisperidone | 21 | $64,365 |
| VraylarCariprazine Hcl | 29 | $43,999 |
| Divalproex Sodium ErDivalproex Sodium | 148 | $16,199 |
| Clozapine OdtClozapine | 23 | $13,951 |
| Quetiapine Fumarate | 391 | $12,712 |
| TrintellixVortioxetine Hydrobromide | 22 | $11,288 |
| Clozapine | 89 | $10,769 |
| Aripiprazole | 174 | $10,432 |
| Olanzapine | 281 | $8,930 |
| Risperidone | 216 | $7,961 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna | $1,592 | $704,965115 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $1,270 | $327,649114 claims |
| Alkermes, Inc.Aristada | $3,007 | $315,659101 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $48,579 | $164,26711 claims |
| Indivior Inc.Perseris | $1,850 | $64,36521 claims |
| AbbVieVraylar | $1,365 | $43,99929 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few psychiatric/mental health, adult providers in Hawaiion file to place this against a meaningful peer group, so we don't.
Other psychiatric/mental health, adult in Honolulu
- Rosario AugustinHonolulu$9K
- Stacy KracherHonolulu$3K
- Vickie GleedHonolulu$492
- Mary MossmanHonolulu$317
- Joseph GiovannoniHonolulu$249
- Jere GrahamKapaa$267
- Suwan McGrathWailuku$102
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.